ipilimumab,nivolumab
bms
['/ipi', 'car-t', 'nivo', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm']
mss crc challenges, panel discussion #asco22 #crcsm kras wt status?
pani+nivo/ipi- ~rr 30%, durable response, need explored
when car-ts are developed, how are we going to do it?
bi-sp abs, car-ts, vaccs, mss 1 bucket, not good, what can be done better in trials 
Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology